The US FDA has approved Amgen's Bkemv as an interchangeable biosimilar to Soliris for the treatment of specific rare diseases ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
Imdelltra, a bispecific antibody targeting a protein called DLL3, is cleared for use following chemotherapy in treating extensive-stage small cell lung cancer.
The FDA has granted accelerated approval to IMDELLTRA™ for treating extensive-stage small cell lung cancer following platinum ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...
Schedule one drugs, such as heroin, are considered highly addictive with no medical benefits, while schedule three drugs are ...
The U.S. Food and Drug Administration on Monday approved Biocon unit's biosimilar to Regeneron Pharmaceuticals' blockbuster ...
The Food and Drug Administration last week approved an innovative new treatment for patients with a form of lung cancer. It ...
Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the ...
Tarlatamab, a bispecific T-cell engager, was approved by the FDA for adults with extensive-stage small cell lung cancer.